Contineum Therapeutics Stock Price, News & Analysis

Contineum Therapeutics (Nasdaq: CTNM) reported its Q3 2024 financial results and recent business highlights. The company continued enrolling patients in its Phase 2 VISTA trial of PIPE-307 for RRMS, achieving two-thirds enrollment. It expects full enrollment by H1 2025. Contineum submitted a CTA to the MHRA for a Phase 1b trial of PIPE-791, targeting healthy volunteers and patients with progressive multiple sclerosis and IPF, aiming to start in December 2024. Janssen Pharmaceutica remains on track to start a Phase 2 trial of PIPE-307 in depression. The company holds $214 million in cash, expected to support operations through 2027. Q3 R&D expenses rose to $9.7 million from $6.5 million YoY, driven by increased costs for ongoing trials and toxicology studies. General and administrative expenses also increased to $3.3 million from $1.6 million YoY, mainly due to higher stock-based compensation and consulting costs.

Contineum Therapeutics (Nasdaq: CTNM), a clinical stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The company, which focuses on developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications, will be represented by its President and CEO, Carmine Stengone.

The conferences are:

• Morgan Stanley 22nd Annual Global Healthcare Conference (September 4-6, 2024, New York) - Presentation on September 4 at 7:00 am ET
• H.C. Wainwright 26th Annual Global Investment Conference (September 9-11, 2024, New York) - Presentation on September 10 at 2:30 pm ET

Both presentations will be available via webcast on Contineum's website, with replays accessible after the events conclude.

Contineum Therapeutics (Nasdaq: CTNM) reported Q2 2024 financial results and recent business highlights. Key points include:

- Strong cash position of $219 million at Q2 end
- Appointed Troy Ignelzi and Sarah Boyce to Board of Directors
- Strengthened management team with John Healy and Kristina Haeckl
- Enrollment on track for PIPE-307 Phase 2 VISTA trial in RRMS
- Published preclinical and clinical results on PIPE-307 and PIPE-791
- Completed IPO with net proceeds of $107.9 million

Financial results:
- R&D expenses: $7.9 million (Q2 2024) vs $9.5 million (Q2 2023)
- G&A expenses: $3.0 million (Q2 2024) vs $1.6 million (Q2 2023)

Contineum Therapeutics (Nasdaq: CTNM) has announced the publication of encouraging preclinical data on PIPE-307, a potentially first-in-class M1 receptor antagonist for relapse-remitting multiple sclerosis (RRMS), in the Proceedings of the National Academy of Science. The data suggest that PIPE-307 is a novel, selective inhibitor of the muscarinic type 1 M1 receptor, which may promote remyelination in multiple sclerosis.

The company has completed two Phase 1 trials in healthy volunteers and initiated a Phase 2 multi-center, randomized, double-blind, placebo-controlled proof-of-concept clinical trial (VISTA) in RRMS patients. This trial will assess efficacy and safety, measuring multiple clinical and imaging endpoints sensitive to changes in remyelination. PIPE-307 is being developed under a global license and development agreement with Janssen Pharmaceutica NV.

Contineum Therapeutics (Nasdaq: CTNM), a clinical-stage biopharmaceutical company, announced its participation in the 45th Annual Goldman Sachs Healthcare Conference, from June 10-13, 2024, in Miami.

Carmine Stengone, President and CEO, will engage in a fireside chat on June 10 at 8:40 am ET, with the event webcast live on Contineum’s website. The company will also hold one-on-one meetings with investors throughout the conference.

Contineum Therapeutics (Nasdaq: CTNM), a clinical-stage biopharmaceutical company, announced the appointment of John Healy as General Counsel & Corporate Secretary. Healy brings over 20 years of legal experience in the life sciences industry, including roles at Tyra Biosciences where he oversaw the company's IPO. He has also provided legal consulting to numerous biotech firms. CEO Carmine Stengone praised Healy's extensive experience and potential to guide Contineum through its growth. Healy expressed enthusiasm about joining Contineum and contributing to its advancement in neuroscience, inflammation, and immunology therapies.

Contineum Therapeutics (Nasdaq: CTNM), a clinical stage biopharma company focusing on neuroscience, inflammation, and immunology therapies, announced the appointment of Troy Ignelzi as an independent board member and Chair of the Audit Committee.

Mr. Ignelzi, currently CFO at Rapport Therapeutics, has nearly two decades of financial leadership. His previous roles include CFO positions at Karuna Therapeutics, Juventas Therapeutics, and scPharmaceuticals. He also has experience with Eli Lilly and other biotech companies.

Mr. Ignelzi's expertise in public markets and financing precision neuroscience companies is expected to aid Contineum's development of therapies targeting fibrotic and neurological disorders.

Contineum Therapeutics (Nasdaq: CTNM) reported financial results for Q1 2024 and announced significant corporate progress. The company successfully completed its IPO, netting $108 million, extending its cash runway to 2027. Key developments include the initiation of a Phase 2 trial for PIPE-307 in RRMS and a planned Phase 1b trial for PIPE-791. Contineum also nominated a third development candidate, CTX-343, and presented positive data on PIPE-791 at the Myelin Gordon Conference. Financially, the company reported $117.9 million in cash and securities, with increased R&D expenses of $7.8 million and G&A expenses of $2.2 million.